Inhibrx Biosciences Inc. (INBX)
INBX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/2007919/000200791926000006/0002007919-26-000006-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | INBX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0002007919 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.3M |
| Net income | -$140.1M |
| Operating income | -$135.0M |
| Net margin | -10773.5% |
| Operating margin | -10386.5% |
| Revenue growth | +550.0% |
| Cash | $124.2M |
| Total assets | $146.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 879.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-13 |
| Cash and burn | $133.3M cash; operating cash flow -$33.0M a quarter. | Report 2026-06-30 |
| Shares outstanding | 14,769,076 (2026-11-06); 14,543,738 a year earlier. | Cover page 2026-11-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-11-13 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | BDO USA, P.C., San Diego, California, United States | PCAOB Form AP 2026-03-20 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $5.5M, sold $11.6M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $0 | -$36.6M | -$29.9M | $133.3M | $176.3M | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | Not filed | -$33.4M | -$38.0M | $161.7M | $175.0M | Needs four quarters | 10-Q 2026-08-13 |
| Q4 2025 2025-12-31 | $0 | -$32.8M | -$30.1M | $124.2M | $100.6M | $1.3M | 10-K 2026-03-19 |
| Q3 2025 2025-09-30 | $0 | -$35.3M | -$33.8M | $153.1M | $99.9M | $1.4M | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | $1.3M | -$28.7M | -$30.0M | $186.6M | $99.3M | $1.4M | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $0 | -$43.3M | -$35.9M | $216.5M | $98.7M | $200K | 10-Q 2025-05-14 |
| Q4 2024 2024-12-31 | $100K | -$47.9M | -$43.7M | $152.6M | $0 | $200K | 10-K 2026-03-19 |
| Q3 2024 2024-09-30 | $0 | -$43.9M | -$30.3M | $196.3M | $0 | $1.7M | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-11-13 |
| Latest annual report | 10-K | 2026-03-19 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-11-13 |
| Latest proxy | DEFA14A | 2026-04-23 |
Source: SEC EDGAR submissions feed, 162 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.4% |
| 1 month | -4.3% |
| 3 months | -14.1% |
| Year to date | +5.4% |
| 1 year | +11.6% |
| From 52-week high | -41.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| VOR | Vor Biopharma Inc. | $18.97 | -2.32% | $1.2B |
| TSHA | Taysha Gene Therapies Inc. | $4.06 | -0.98% | $1.3B |
| NVAX | Novavax Inc. | $8.06 | -5.45% | $1.3B |
| ODTX | Odyssey Therapeutics Inc. | $19.36 | +1.15% | $930.6M |
| IMTX | Immatics N.V. | $6.17 | -3.44% | $923.2M |
| LYCA | Lycia Therapeutics Inc. | $28.61 | -8.30% | $1.5B |
| IMCR | Immunocore Holdings plc | $28.88 | -3.54% | $1.5B |
| MGTX | MeiraGTx Holdings plc | $8.74 | -4.79% | $854.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier